WCESP (2 mg/ml) decreases <i>V</i>. <i>cholerae</i> cell-surface hydrophobicity. by Daniel B. Pederson (604306)

Decreased motor neuron survival in E18.5 GAD67-deficient (−/−) hypoglossal and phrenic motor nuclei. by Matthew J. Fogarty (283288)

Intrathecal KN93 injection attenuated fentanyl-induced hyperalgesia and decreased the level of <i>p</i>-CaMKIIα in spinal cord but not CeLC in OIH rats. by Zhen Li (1234644)

Botulinum toxin A (3.5 U/kg) decreases dural extravasation in IoNC injured rats. by Boris Filipović (336089)

Retnla overexpression decreased the levels of IL-4, IL-5, and IL-13 in OVA-induced asthmatic lung. by Mi-Ran Lee (664596)

Expression of specific proteins in PANDER-overexpressing C57BL/6 mice. by Xiaoqing Mo (2217691)

BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma. by Zahra Motahari (6814013)

Genomic inactivation of the <i>PIWI</i> gene in <i>L. infantum</i> and <i>L. major</i> strains leads to a decrease in amastigote growth and disease pathology. by Prasad K. Padmanabhan (85254)

Archazolid decreases the activity and expression of cathepsin B in endothelial cells. by Betty Luong (5738027)

Neutrophils adhered to the apical surface of polarized-MDCK cells augment AdV entry without decreasing the TER. by Poornima L. N. Kotha (701665)

Figure 5 from Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin by Joanna Domagala (21643925)

“…<p>Ammonia decreases the amount of mature perforin in NK cells. …”

pGab1 levels decreased over time in HCV-infected Huh7.5.1 cells. by Da-eun Nam (18927946)

A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

“…<i>eIF4α</i> was used as an internal control. Values represent means ± SE from three independent experiments. <b>(C)</b> The mutant CLCuMuV carrying C4^R13A (CLCuMuV-C4^R13A), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”

Infection decreases short chain phospholipids in the intestines of <i>V</i>. <i>cholerae</i>-infected flies. by Audrey S. Vanhove (4090594)

The mean values of correctly memorized foreground characters and users’ SDNN in different background line orientations. by Yanqun Huang (7487657)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”